These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 11484704

  • 21. Meyerson's phenomenon induced by interferon-alfa plus ribavirin in hepatitis C infection.
    Girard C, Bessis D, Blatìre V, Guilhou JJ, Guillot B.
    Br J Dermatol; 2005 Jan; 152(1):182-3. PubMed ID: 15656829
    [No Abstract] [Full Text] [Related]

  • 22. Does antidepressant medication in patients with hepatitis C undergoing interferon alpha treatment reduce therapeutic efficacy?
    Robaeys G, Wichers MC, De Bie J, Koek GH, Buntinx F, Van Os J.
    Gut; 2009 Jan; 58(1):145; author reply 145-6. PubMed ID: 19091833
    [No Abstract] [Full Text] [Related]

  • 23. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.
    Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Heinze L, Spengler U, Schlaepfer T, Reimer J, Buggisch P, Ockenga J, Link R, Rentrop M, Weidenbach H, Fromm G, Lieb K, Baumert TF, Heinz A, Discher T, Neumann K, Zeuzem S, Berg T.
    Ann Intern Med; 2012 Jul 17; 157(2):94-103. PubMed ID: 22801672
    [Abstract] [Full Text] [Related]

  • 24. The successful use of electroconvulsive therapy in a patient with interferon-induced psychotic depression.
    Zincke MT, Kurani A, Istafanous R, Kellner C.
    J ECT; 2007 Dec 17; 23(4):291-2. PubMed ID: 18090708
    [Abstract] [Full Text] [Related]

  • 25. Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study.
    Pavlović Z, Delić D, Marić NP, Vuković O, Jašović-Gašić M.
    Psychiatr Danub; 2011 Dec 17; 23(4):370-7. PubMed ID: 22075738
    [Abstract] [Full Text] [Related]

  • 26. Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C.
    Kraus MR, Al-Taie O, Schäfer A, Pfersdorff M, Lesch KP, Scheurlen M.
    Gastroenterology; 2007 Apr 17; 132(4):1279-86. PubMed ID: 17408646
    [Abstract] [Full Text] [Related]

  • 27. Paroxetine/bupropion combination treatment for refractory depression.
    Marshall RD, Liebowitz MR.
    J Clin Psychopharmacol; 1996 Feb 17; 16(1):80-1. PubMed ID: 8834426
    [No Abstract] [Full Text] [Related]

  • 28. Generalized nummular eczema secondary to peginterferon Alfa-2b and ribavirin combination therapy for hepatitis C infection.
    Shen Y, Pielop J, Hsu S.
    Arch Dermatol; 2005 Jan 17; 141(1):102-3. PubMed ID: 15655158
    [No Abstract] [Full Text] [Related]

  • 29. Paroxetine: a review of clinical experience.
    Dunner D, Kumar R.
    Pharmacopsychiatry; 1998 May 17; 31(3):89-101. PubMed ID: 9657236
    [Abstract] [Full Text] [Related]

  • 30. The management of side-effects during therapy for hepatitis C.
    Aspinall RJ, Pockros PJ.
    Aliment Pharmacol Ther; 2004 Nov 01; 20(9):917-29. PubMed ID: 15521838
    [Abstract] [Full Text] [Related]

  • 31. Meyerson's naevi induced by interferon alfa plus ribavirin combination therapy in hepatitis C infection.
    Conde-Taboada A, de la Torre C, Feal C, Mayo E, Gonzalez-Sixto B, Cruces MJ.
    Br J Dermatol; 2005 Nov 01; 153(5):1070-2. PubMed ID: 16225630
    [No Abstract] [Full Text] [Related]

  • 32. Adverse response to pegylated interferon therapy in two patients with chronic hepatitis C.
    Thomas WL, Ramos F, Hospenthal DR.
    Hawaii Med J; 2003 Aug 01; 62(8):163-4. PubMed ID: 14533347
    [Abstract] [Full Text] [Related]

  • 33. Resolution of treatment-refractory depression with naltrexone augmentation of paroxetine--a case report.
    Amiaz R, Stein O, Dannon PN, Grunhaus L, Schreiber S.
    Psychopharmacology (Berl); 1999 Apr 01; 143(4):433-4. PubMed ID: 10367562
    [No Abstract] [Full Text] [Related]

  • 34. Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.
    Nouri K, Busso M, Machler BC.
    Cutis; 1997 Dec 01; 60(6):289-90. PubMed ID: 9426968
    [Abstract] [Full Text] [Related]

  • 35. Generalized exfoliative dermatitis induced by interferon alfa.
    Gallelli L, Ferraro M, Mauro GF, De Sarro G.
    Ann Pharmacother; 2004 Dec 01; 38(12):2173-4. PubMed ID: 15522975
    [No Abstract] [Full Text] [Related]

  • 36. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Rogers CJ, Romagosa R, Vincek V.
    J Am Acad Dermatol; 2004 Apr 01; 50(4):649-50. PubMed ID: 15034524
    [No Abstract] [Full Text] [Related]

  • 37. Withdrawal after discontinuation of paroxetine.
    Arya DK.
    Aust N Z J Psychiatry; 1996 Oct 01; 30(5):702. PubMed ID: 8902183
    [No Abstract] [Full Text] [Related]

  • 38. Sexual dysfunction in males with chronic hepatitis C and antiviral therapy: interferon-induced functional androgen deficiency or depression?
    Kraus MR, Schäfer A, Bentink T, Scheurlen M, Weissbrich B, Al-Taie O, Seufert J.
    J Endocrinol; 2005 May 01; 185(2):345-52. PubMed ID: 15845927
    [Abstract] [Full Text] [Related]

  • 39. Angioedema after interferon therapy for chronic hepatitis C.
    Ohmoto K, Yamamoto S.
    Am J Gastroenterol; 2001 Apr 01; 96(4):1311-2. PubMed ID: 11316204
    [No Abstract] [Full Text] [Related]

  • 40. Pegylated interferon alfa-induced sarcoidosis: two sides of the same coin.
    Guilabert A, Bosch X, Julià M, Iranzo P, Mascaró JM.
    Br J Dermatol; 2005 Feb 01; 152(2):377-9. PubMed ID: 15727663
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.